1. US Food and Drug Administration. FDA approves relugolix for advanced prostate cancer. Silver Spring, MD: US FDA; 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-relugolix-advanced-prostate-cancer.
2. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer;Shore;N Engl J Med,2020
3. Center for Drug Evaluation and Research. NDA/BLA multi-disciplinary review and evaluation. NDA 214, 621 relugolix. Silver Spring, MD: US FDA; 2020. pp. 106, 112, Table 10. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000MultidisciplineR.pdf.
4. Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?;Tolkach;BJU Int,2013
5. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer;Klotz;BJU Int,2008